CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 150 target
Drug / intervention
Template Lymph Node Dissection +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07321210
NCT07321210N/ARecruitingOn Track

Clinical Efficacy and Safety of Radical Nephroureterectomy With Versus Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma: A Multicenter, Prospective, Randomized Controlled Clinical Trial

Tianjin Medical University Second Hospital·interventional·Posted Jan 6, 2026·Updated Jun 25, 2026

In Brief

A clinical study evaluating Template Lymph Node Dissection and Selective Lymph Node Resection for Upper Tract Urothelial Carcinoma and Lymph Node Dissection. Currently recruiting, targeting 150 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to learn if adding a template lymph node dissection (TLND) to the standard surgery for upper tract urothelial cancer (UTUC) can improve patient survival and prevent the cancer from recurrence. The main questions it aims to answer are: Do patients who receive standard surgery with LND live longer without their cancer returning? Is adding LND safe, and how does it affect surgery-related complications? Researchers will compare the group receiving standard surgery plus LND to the group receiving standard surgery alone to see if adding LND is more effective. Participants will: Be randomly assigned to one of the two surgical groups. Undergo their assigned surgery and recover in the hospital. Attend regular follow-up visits for checkups and scans for 5 years to monitor for cancer recurrence, with the possibility of long-term follow-up extending to 10 years.

Study Details

Timeline

N/ARecruiting
2026202720282029203020312032
First PostedJan 6, 2026
Enrollment StartSep 1, 2025
Primary CompletionAug 30, 2027
Study CompletionAug 30, 2032
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 6 months agoPrimary completion in 1.2 years

Arms & Interventions

RNU + Template Lymph Node Dissectionexperimental

Participants in this arm will undergo Radical Nephroureterectomy (RNU) combined with template Lymph Node Dissection (LND). The LND will be performed according to a predefined template based on the primary tumor location: renal hilum+para-aortic (left hilar and paraaortic) or renal hilum+para-caval (right hilar, paracaval, and interaortocaval) for renal pelvis/upper ureter; extended to common/external iliac for mid-ureter; and pelvic (common, external, internal iliac, and obturator) for lower ureter. The surgical approach (open, laparoscopic, or robot-assisted) is at the surgeon's discretion.

Procedure: Template Lymph Node Dissection
RNU + Selective Lymph Node Resectionactive_comparator

Participants in this arm will undergo Radical Nephroureterectomy (RNU) alone. No template lymph node dissection will be performed. However, if intraoperatively identified suspicious and radiographic lymphadenopathy (\>1 cm in the short-axis diameter) are present, they may be removed for pathological staging purposes only.

Procedure: Selective Lymph Node Resection

Interventions

Template Lymph Node Dissectionprocedure

A systematic and anatomic-based lymph node dissection performed during radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). The dissection boundaries are strictly defined by a pre-specified template according to the primary tumor location: renal hilum+para-aortic (left hilar and paraaortic) or renal hilum+para-caval (right hilar, paracaval, and interaortocaval) for renal pelvis/upper ureter; extended to common/external iliac for mid-ureter; and pelvic (common, external, internal iliac, and obturator) for lower ureter. The goal is potential therapeutic benefit by removing nodal metastatic disease.

Selective Lymph Node Resectionprocedure

A diagnostic procedure performed during radical nephroureterectomy (RNU). It does not involve a systematic template dissection. The surgeon will only remove intraoperatively identified suspicious and radiographic lymphadenopathy (\>1 cm in the short-axis diameter). The primary goal is pathological staging rather than therapeutic clearance of a nodal basin.